⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dioxane SCHEMBL25302481 | 0.86 | MEN1 (0.35) | — | |
| SCHEMBL5509841 | 0.76 | — | — | |
| SCHEMBL21384409 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL29132895 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL25188589 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL27624459 | 0.74 | TSHR (0.31) | — | |
| SCHEMBL3611613 | 0.72 | SOS1 (0.31) | — | |
| SCHEMBL92498 | 0.69 | — | — | |
| SCHEMBL4002326 | 0.67 | SIGMAR1 (0.32) | — | |
| Hydrochloric Acid SCHEMBL70859 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-14 | — | — | US | disclosed |
| US-20250171457-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-05-29 | — | — | US | disclosed |
| US-20250084093-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-03-13 | — | — | US | disclosed |
| WO-2025026283-A1 | COMPOUND FOR SELECTIVELY DEGRADING SMARCA2/4 AND USE THEREOF | 甘李药业股份有限公司 | 2025-02-06 | — | — | WO | disclosed |
| EP-4446312-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-10-16 | — | — | EP | disclosed |
| CN-118488944-A | Nitrogen-containing heterocyclic compound having Nrf2 activation | 中外制药株式会社 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023132369-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | 中外製薬株式会社 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023132369-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | 中外製薬株式会社 | 2023-07-13 | — | — | WO | disclosed |
| CN-111362852-B | Preparation method of medicine intermediate 1-tert-butoxycarbonyl-3-azetidinone | 浙江瑞博制药有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-111362852-A | Preparation method of drug intermediate 1-tert-butyloxycarbonyl-3-azetidinone | 浙江瑞博制药有限公司 | 2020-07-03 | — | — | CN | disclosed |